

Certificate of Analysis

BDG Synthesis certifies that this reference material meets or exceeds the specifications stated herein.

loil Beare

Neil Beare, PhD, Director 10 October 2016

Name: Acyclovir-d4

CAS Number: 59277-89-3 (unlabelled)

Structure:

$$\begin{array}{c|c} O & & & \\ & & & \\ H_2N & & & \\ D & & & \\ D & & \\ D & & \\ \end{array}$$

Molecular Weight: $C_8H_7D_4N_5O_3 = 229.23$

Lot Number: BDG 12323.3

Appearance: White, crystalline solid

Purity By HPLC: 98.6 %

Isotopic Purity: Under 0.5 % d₀ **Re-test Date:** 10 October 2021

Storage and Handling: Temperature: refrigerate for prolonged storage; may be handled and shipped at

ambient temperature.

Humidity: not believed to be hygroscopic; may be handled in normal laboratory

atmosphere.

Light: protect from strong sunlight.

Caution: only experienced laboratory personnel should handle the material.

Custom synthesis

Identity and Purity

Proton NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available. Isotopic Labelling: signals at the sites of deuteration are greatly diminished, compared with what would be expected for unlabelled material, indicating clean deuteration.

Residual Solvents: a trace (under 0.1 % w/w) of methanol is observed.

Impurities: no significant impurities are evident in the spectrum.

Carbon-13 NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available. Isotopic Labelling: signals at the sites of deuteration have collapsed to small multiplets compared with what would be expected for unlabelled material, indicating clean deuteration.

High-resolution Mass Spectrum (ESI+)

Found m/z 230.1185. $C_8H_8D_4N_5O_3$ [M+H]⁺ requires m/z 230.1191. The deviation of 2.6 ppm is within normally accepted limits for the establishment of identity by HRMS. No signal for d_0 material was seen (detection limit about 0.5 %).

HPLC

A sharp, symmetrical peak is observed (98.6 %). Note: in the absence of reference materials for preparing calibration curves, it is assumed that all peaks have the same detector response. Where possible, the conditions of analysis follow a pharmacopeial or literature method, or have been adapted from same.

Elemental Analysis

Found: C 41.72, H 2.97, D 3.40, N 30.71 % Requires: C 41.92, H 3.08, D 3.51, N 30.55 %


The elemental analyses fall within generally accepted limits for establishing the molecular formula given. The results may also be taken to imply the absence of significant quantities of water or inorganic salts (which have not been elsewhere tested for because of sample size limitations).

The available quantity of custom-synthesised material is always small, and this limits the extent and type of analytical data which can be obtained. This Certificate is presented in descriptive format for use by analytical chemists who are trained in the use of custom-synthesised materials. Custom materials often contain higher levels of residual solvents and/or water, and we urge you to use the corrected purity where needed rather than the raw HPLC purity. This compound is intended for use as an analytical reference material and it is not for human administration. Structures are shown with relative stereochemistry unless otherwise specified.


The re-test date is assigned from experience gained with the material in the laboratory and/or on storage. It is not possible to perform formal storage studies because of the small amount of material available.



BDG SYNTHESIS



Lot Number: BDG 12323.3



BDG - Analysis of Acyclovir-d4


Column: Phenomenex Luna C18(2) 5um 250 x 4.6 mm Guard: Phenomenex Security Guard C18 RP 4 x 3 mm

Mobile Phase : 92:8 IP : Acetonitrile IP = 38 mM Sodium diHydrogen Phosphate + 3.5 mM Sodium Dodecylsulphate pH=3.0 (H3PO4)

Flow Rate: 1.5 mL/min

Sample Solvent: 20% Acetic Acid Column Temperature: 25 C Injection Volume: 10 uL Detection: UV at 254 nm

| Sample Name | BDG 12323.3 | Instrument | AnalyticalLC01 |
|-------------|------------------------------|---------------|-----------------|
| Acquisition | 10/10/2016, 17:52:58 | Method (rev.) | LC10384b (18) |
| Sequence | BDG_10Oct2016b - Reprocessed | Vial Position | 1 |
| Operator | solvation010\cerityadmin | Injection | 1 of 1 |



Area Percent Report

| Peak# | RT | Peak Height | Peak Area | Width | Area % |
|-------|-----------|-------------|------------|------------|----------|
| 1 | 4.53 min | 0.5266 | 5.2645 | 0.1366 min | 0.023 % |
| 2 | 5.84 min | 1215.0126 | 22730.9720 | 0.2543 min | 98.573 % |
| 3 | 6.62 min | 5.6519 | 70.6845 | 0.1939 min | 0.307 % |
| 4 | 7.74 min | 0.2250 | 2.1409 | 0.1230 min | 0.009 % |
| 5 | 16.44 min | 1.5071 | 54.8427 | 0.5045 min | 0.238 % |
| 6 | 30.76 min | 3.1918 | 196.0606 | 0.7646 min | 0.850 % |